CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
CSL announced an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases. The deal is worth up to $1.6 billion before development funding.
Why it matters — The agreement expands CSL's pipeline and commercial reach into rare disease treatments through a significant co-development partnership.